Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis

Not Applicable

Completed

• Conditions: Psoriatic Arthritis
• Interventions: Drug: Fecal microbiota transplantation (FMT); Drug: Methotrexate (MTX)

• Registration Number: NCT03058900
• Lead Sponsor: Odense University Hospital

Brief Summary

An abnormal intestinal microbiota may be the mediator of the common inflammatory pathways seen in psoriatic arthritis. This study will explore clinical aspects associated with modifying the intestinal microbiota by infusing fecal donor microbiota into the small intestine of psoriatic arthritis patients with a minimum of three swollen joints despite at least three months of methotrexate treatment.

Detailed Description

Recent years have seen growing recognition of the complexity of the role of the microbiota in shaping the immune system and its potential effects for health and disease. In particular, the gut bacteria composition has been associated with the pathogenesis of autoimmune and inflammatory diseases. Intriguingly, presence of intestinal inflammation in psoriatic arthritis (PsA) patients has been documented in several studies. Also, in genetically predisposed patients reactive arthritis, which share some of the clinical manifestations of PsA, can be triggered by certain types of bacterial gut infections. Furthermore, a recent study has reported that several intestinal bacteria including Akkermansia and Ruminoccocus, which are known to play an important role in maintaining gut homeostasis, were practically absent in PsA patients. Mechanisms through which the microbiota may be involved in the pathogenesis of PsA include an abnormal activation of the gut-associated lymphoid tissue (GALT) and/or an altered mucosal permeability thus compromising the capacity of the intestine to provide adequate containment of luminal microorganisms and molecules.

By conducting a double-blinded, randomized, placebo-controlled trial of a non-related donor fecal microbiota transplantation (FMT) infused into the small intestine, this study will reveal whether FMT is more effective than an identically appearing placebo (saline) in reducing disease activity in psoriatic arthritis patients presenting with a minimum of three swollen joints despite at least three months of methotrexate treatment (maximal tolerable dosis ≥ 15 mg/week). All patients will throughout the study continue their individual treatment with weekly methotrexate.

Study Timeline

• Study First Submitted: 2017-02-13
• Study First Submitted QC: 2017-02-16
• Study First Posted: 2017-02-23
• Study Start: 2017-05-16
• Primary Completion: 2020-06-02
• Study Completion: 2020-06-02
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-04
• Last Update Posted: 2020-12-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

• Diagnosis of psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR criteria).
• Presence of active peripheral psoriatic arthritis defined as ≥ 3 swollen joints.
• Methotrexate (≥ 15mg/week (maximal tolerable dosage)) for a minimum of 3 months prior to study inclusion.

Read More

Exclusion Criteria

• Other inflammatory rheumatic diseases than PsA.
• Current axial disease activity or severe peripheral joint activity demanding immediate change of treatment or contraindicating placebo treatment for 6 months.
• History of severe MTX toxicity or allergic reactions.
• Current biological treatment and biological treatment within the last 6 months.
• Inflammatory bowel disease, celiac disease, food allergy, or other intestinal diseases.
• Current cancer or severe chronic infections.
• Pregnant or breastfeeding women.
• Systemic and/or local intra-articular or peritendinous steroid injections within 3 months of inclusion.
• Non-MTX DMARD treatment within three months of inclusion.
• Antibiotics within 3 months of inclusion.
• Not wishing to participate or unsuited for project evaluation.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Fecal microbiota transplantation (FMT)	Methotrexate (MTX)	-
Fecal microbiota transplantation (FMT)	Fecal microbiota transplantation (FMT)	-
Placebo (saline)	Methotrexate (MTX)	-

Primary Outcome Measures

Name	Time	Method
Treatment failure	6 months (+/- 14 days)	Proportion of patients in each group who experience treatment failure according to shared decision making between patient and rheumatologist defined as at least one of the following: * Need for more than 1 intra-articular glucocorticoid injection due to disease activity.; * Need for change to other conventional DMARDs (at the moment oral leflunomide, sulfasalazin or ciclosporin) according to the updated Danish guideline treatment due to disease activity.; * Need for biologic treatment according to the updated Danish guideline treatment due to severe disease activity.

Secondary Outcome Measures

Name	Time	Method
Number of Adverse Events	6 months (+/- 14 days)	Number of adverse events in each group.
The Short Health Assessment Questionnaire (2-page HAQ)	Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days)	Change from baseline in the Short Health Assessment Questionnaire (2-page HAQ).
The Psoriatic Arthritis Response Criteria (PsARC)	Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)	Proportion of patients in each group achieving PsARC response criteria. A patient will be considered as improved according to the PsARC response criteria if she/he has an improvement in either joint swelling or tenderness, and in any of 4 other measures: Patient global assessment of articular disease; physician global assessment of articular disease; joint pain or tenderness; joint swelling.
The Dermatology Life Quality Index (DLQI) Questionnaire	Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days)	Change from baseline in the Dermatology Life Quality Index (DLQI).
Patient Reported Gastrointestinal Side Effects	Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days)	Change from baseline in gastrointestinal symptoms.
Patient Reported Other Side Effects	Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days)	Change from baseline in other (non-gastrointestinal) symptoms.
The Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index	Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)	Change from baseline in SPARCC Enthesitis Index in the subset of patients who have enthesitis at baseline.
The American College of Rheumatology (ACR) Response Criteria	Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)	Proportion of patients in each group achieving; * ACR20 response criteria; * ACR50 response criteria; * ACR70 response criteria; A patient will be considered as improved according to the ACR20/50/70 response criteria if she/he has at least 20/50/70% improvement in the two following measures: Tender joint count (68) and swollen joint count (66), and at least 3 of the following 5 measures: Patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ) score, acute phase reactant (CRP).
The Psoriasis Area Severity Index (PASI)	Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)	Change from baseline in the Psoriasis Area Severity Index (PASI) in the subset of patients who have psoriasis at baseline.
Number of Patients with Adverse Events	6 months (+/- 14 days)	Number of patients with at least one adverse event in each group.
Dactylitis	Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days)	Change from baseline in the number of digits affected with dactylitis in the subset of patients who have dactylitis at baseline.

Trial Locations

Locations (2)

Dept. of Rheumatology at Odense University Hospital; 🇩🇰 Odense, Denmark

Diagnostic Centre at Silkeborg Regional Hospital; 🇩🇰 Silkeborg, Denmark